Skip to main content
Top
Published in: Drugs & Aging 8/2017

01-08-2017 | Original Research Article

Older People’s Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment

Authors: Veerle H. Decalf, Anja M. J. Huion, Dries F. Benoit, Marie-Astrid Denys, Mirko Petrovic, Karel C. M. M. Everaert

Published in: Drugs & Aging | Issue 8/2017

Login to get access

Abstract

Introduction

Understanding the importance older people attribute to the different side effects associated with oral antimuscarinic treatments for overactive bladder (OAB) could help inform prescribers, healthcare policy makers and the drug industry.

Objective

Our objective was to quantify the importance of the most prevalent cognitive and side effects of oral antimuscarinic treatments for OAB in older people.

Methods

We conducted a discrete-choice experiment (DCE) with the assistance of an interviewer with community-dwelling and hospitalized older people aged >65 years. The DCE involved two hypothetical drugs for imaginary OAB, with three levels of four side effects for each drug, and the International Consultation on Incontinence Questionnaire–Overactive Bladder and EuroQol 5-Dimensions (EQ-5D) questionnaire were also administered. Data were analysed using a conditional logit model.

Results

In total, 276 older people participated in the study. The median age was 75 years (interquartile range [IQR] 69–80), 63% were women and 21% had OAB syndrome. The most unwanted side effect in the choice of antimuscarinics for OAB was severe cognitive effects, followed by severe constipation, severe blurred vision, severe dry mouth, moderate cognitive effects and moderate constipation. Severe cognitive effects were at least 1.7 times as important as severe constipation. Exploratory subgroup analysis showed that none of the attributes was found to be significant in people who scored as anxious or depressed on the EQ-5D, and preferences about cognitive effects, constipation and blurred vision were equal in people with and without OAB.

Conclusion

Older people attribute more importance to loss of cognitive function as a possible side effect of antimuscarinic treatment than to the three most prevalent possible side effects of this treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–15.CrossRefPubMed Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–15.CrossRefPubMed
2.
go back to reference Temml C, Heidler S, Ponholzer A, et al. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol. 2005;48:622–7.CrossRefPubMed Temml C, Heidler S, Ponholzer A, et al. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol. 2005;48:622–7.CrossRefPubMed
3.
go back to reference Agarwal A, Eryuzlu LN, Cartwright R, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014;65:1211–7.CrossRefPubMedPubMedCentral Agarwal A, Eryuzlu LN, Cartwright R, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014;65:1211–7.CrossRefPubMedPubMedCentral
4.
go back to reference Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49.CrossRefPubMed Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49.CrossRefPubMed
5.
go back to reference Sexton CC, Coyne KS, Thompson C, et al. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc. 2011;59:1465–70.CrossRefPubMed Sexton CC, Coyne KS, Thompson C, et al. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc. 2011;59:1465–70.CrossRefPubMed
6.
go back to reference Wagg A, Gibson W, Ostaszkiewicz J, et al. Urinary incontinence in frail elderly persons: report from the 5th International Consultation on Incontinence. Neurourol Urodyn. 2015;34:398–406.CrossRefPubMed Wagg A, Gibson W, Ostaszkiewicz J, et al. Urinary incontinence in frail elderly persons: report from the 5th International Consultation on Incontinence. Neurourol Urodyn. 2015;34:398–406.CrossRefPubMed
8.
go back to reference Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–78.CrossRefPubMedPubMedCentral Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–78.CrossRefPubMedPubMedCentral
9.
go back to reference Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100:987–1006.CrossRefPubMed Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100:987–1006.CrossRefPubMed
10.
go back to reference Vouri SM, Kebodeaux CD, Stranges PM, et al. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2017;69:77–96. doi:10.1016/j.archger.2016.11.006.CrossRef Vouri SM, Kebodeaux CD, Stranges PM, et al. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2017;69:77–96. doi:10.​1016/​j.​archger.​2016.​11.​006.CrossRef
11.
go back to reference Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc. 2011;59:1332–9.CrossRefPubMed Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc. 2011;59:1332–9.CrossRefPubMed
12.
go back to reference Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44:745–55.CrossRefPubMedPubMedCentral Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44:745–55.CrossRefPubMedPubMedCentral
14.
go back to reference Commission Productivity. Trends in aged care services: some implications. Canberra: Commission Research Paper; 2008. Commission Productivity. Trends in aged care services: some implications. Canberra: Commission Research Paper; 2008.
15.
go back to reference Ziegler DK, Mosier M, Buenaver M, et al. How much information about adverse effects of medication do patients want from physicians? Arch Intern Med. 2001;161(5):706–13.CrossRefPubMed Ziegler DK, Mosier M, Buenaver M, et al. How much information about adverse effects of medication do patients want from physicians? Arch Intern Med. 2001;161(5):706–13.CrossRefPubMed
16.
go back to reference Swinburn P, Lloyd A, Ali S, et al. Preferences for antimuscarinic therapy for overactive bladder. BJU Int. 2011;108(6):868–73.PubMed Swinburn P, Lloyd A, Ali S, et al. Preferences for antimuscarinic therapy for overactive bladder. BJU Int. 2011;108(6):868–73.PubMed
17.
go back to reference Heisen M, Baeten SA, Verheggen BG, et al. Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. Curr Med Res Opin. 2016;32(4):787–96.CrossRefPubMed Heisen M, Baeten SA, Verheggen BG, et al. Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. Curr Med Res Opin. 2016;32(4):787–96.CrossRefPubMed
18.
go back to reference Ratcliffe J, Laver K, Couzner L, et al. Not just about costs: the role of health economics in facilitating decision making in aged care. Age Ageing. 2010;39:426–9.CrossRefPubMed Ratcliffe J, Laver K, Couzner L, et al. Not just about costs: the role of health economics in facilitating decision making in aged care. Age Ageing. 2010;39:426–9.CrossRefPubMed
19.
go back to reference Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14:403–13.CrossRefPubMed Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14:403–13.CrossRefPubMed
20.
go back to reference Johnson FR, Lancsar E, Marschall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16:3–13.CrossRef Johnson FR, Lancsar E, Marschall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16:3–13.CrossRef
21.
go back to reference Hauber AB, González JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19:300–15.CrossRefPubMed Hauber AB, González JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19:300–15.CrossRefPubMed
22.
go back to reference Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65:755–65.CrossRefPubMed Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65:755–65.CrossRefPubMed
23.
go back to reference Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–62.CrossRefPubMed Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–62.CrossRefPubMed
24.
go back to reference Corner L, Bond J. Being at risk of dementia: fears and anxieties of older adults. J Aging Stud. 2004;18:143–55.CrossRef Corner L, Bond J. Being at risk of dementia: fears and anxieties of older adults. J Aging Stud. 2004;18:143–55.CrossRef
26.
go back to reference Harrison M, Rigby D, Vass C, et al. Risk as an attribute in discrete choice experiments: a systematic review of the literature. Patient. 2014;7:151–70.CrossRefPubMed Harrison M, Rigby D, Vass C, et al. Risk as an attribute in discrete choice experiments: a systematic review of the literature. Patient. 2014;7:151–70.CrossRefPubMed
28.
go back to reference Milte R, Ratcliffe J, Chen G, et al. Cognitive overload? An exploration of the potential impact of cognitive functioning in discrete choice experiments with older people in health care. Value Health. 2014;17:655–9.CrossRefPubMed Milte R, Ratcliffe J, Chen G, et al. Cognitive overload? An exploration of the potential impact of cognitive functioning in discrete choice experiments with older people in health care. Value Health. 2014;17:655–9.CrossRefPubMed
30.
go back to reference Abrams P, Avery K, Gardener N, et al. The international consultation on incontinence modular questionnaire: www.iciq.net. J Urol. 2006;175:1063–6.CrossRefPubMed Abrams P, Avery K, Gardener N, et al. The international consultation on incontinence modular questionnaire: www.iciq.net. J Urol. 2006;175:1063–6.CrossRefPubMed
31.
go back to reference Marshall D, Bridges JFP, Hauber B, et al. Conjoint analysis applications in health—how are studies being designed and reported? Patient. 2010;3:249–56.CrossRefPubMed Marshall D, Bridges JFP, Hauber B, et al. Conjoint analysis applications in health—how are studies being designed and reported? Patient. 2010;3:249–56.CrossRefPubMed
32.
go back to reference Roiser J, Nathan P, Mander A, et al. Assessment of cognitive safety in clinical drug development. Drug Discov Today. 2016;21:445–53.CrossRefPubMed Roiser J, Nathan P, Mander A, et al. Assessment of cognitive safety in clinical drug development. Drug Discov Today. 2016;21:445–53.CrossRefPubMed
33.
go back to reference Lingler J, Nightingale M, Erlen J, et al. Making sense of mild cognitive impairment: a qualitative exploration of the patient’s experience. Gerontologist. 2006;46:791–800.CrossRefPubMed Lingler J, Nightingale M, Erlen J, et al. Making sense of mild cognitive impairment: a qualitative exploration of the patient’s experience. Gerontologist. 2006;46:791–800.CrossRefPubMed
34.
go back to reference Wagg A. Antimuscarinic treatment in overactive bladder: special considerations in elderly patients. Drugs Aging. 2012;29:539–48.CrossRefPubMed Wagg A. Antimuscarinic treatment in overactive bladder: special considerations in elderly patients. Drugs Aging. 2012;29:539–48.CrossRefPubMed
35.
go back to reference Clarck MD, Determann D, Petrou S, et al. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32:883–902.CrossRef Clarck MD, Determann D, Petrou S, et al. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32:883–902.CrossRef
37.
go back to reference Kay GG, Abou-Donia MB, Messer WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53:2195–201.CrossRefPubMed Kay GG, Abou-Donia MB, Messer WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53:2195–201.CrossRefPubMed
Metadata
Title
Older People’s Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment
Authors
Veerle H. Decalf
Anja M. J. Huion
Dries F. Benoit
Marie-Astrid Denys
Mirko Petrovic
Karel C. M. M. Everaert
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2017
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-017-0474-6

Other articles of this Issue 8/2017

Drugs & Aging 8/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.